FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
RBC Capital analyst Gregory Renza raised the price target on Viridian Therapeutic (NASDAQ: VRDN) to $44.00 (from $35.00) while maintaining a Outperform rating.
The analyst comments "This week's pivotal ph.III THRIVE topline for veligrotug (Veli'; VRDN-001 IV) in active TED came in as a... More

